转移性激素敏感性前列腺癌新型内分泌治疗疗效预测指标的研究进展  

Research progress on predictive indicators of the efficacy of novel endocrine therapy for metastatic hormone-sensitive prostate cancer

作　　者：杨溢泉 齐琳[1] 蔡燚 Yang Yiquan;Qi lin;Cai Yi(Department of Urology,Xiangya Hospital,Central South University,Changsha 410008,China)

机构地区：[1]中南大学湘雅医院泌尿外科,长沙410008

出　　处：《中华泌尿外科杂志》2025年第3期233-236,共4页Chinese Journal of Urology

摘　　要：早期发现前列腺癌并选择最佳治疗方案对改善患者预后十分重要。研究结果显示,根据治疗后PSA动力学变化、雄激素受体及前列腺特异性膜抗原表达量、循环肿瘤细胞、基因突变等指标可预测雄激素剥夺治疗联合新型内分泌治疗及化疗的疗效。此外,构建多因素预测模型并结合肿瘤负荷和转移时序可进一步指导治疗方案的选择。本文旨在为转移性激素敏感性前列腺癌(mHSPC)患者个体化治疗提供更为丰富的证据支持。Research has shown that the efficacy of androgen deprivation therapy in combination with novel hormonal therapies and chemotherapy can be predicted based on several biomarkers,including changes in PSA kinetics following treatment,expression levels of the androgen receptor and prostate-specific membrane antigen,circulating tumor cells,and gene mutations.Moreover,constructing a multivariate prediction model that incorporates tumor burden and metastasis timing can provide additional guidance for selecting appropriate treatment options.This article aims to provide robust evidence to support individualized treatment approaches for patients with metastatic hormone-sensitive prostate cancer(mHSPC).

关 键 词：前列腺肿瘤 转移性激素敏感性前列腺癌 新型内分泌治疗 预测指标 预后 

分 类 号：R737.25[医药卫生—肿瘤]